FDA Panel Unanimously Endorses Lecanemab for Alzheimer's
FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug's clinical benefit for patients with Alzheimer's disease.
Medscape Medical News
source https://www.medscape.com/viewarticle/993055?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/993055?src=rss
Comments
Post a Comment